Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2a, randomized, double-blind, placebo-controlled, dose-escalation study to assess the safety and pharmacodynamics of ISIS 301012 [mipomersen sodium] in hypercholesterolemic subjects on stable statin therapy.

Next Previous
X
Search
Trial Profile

A phase 2a, randomized, double-blind, placebo-controlled, dose-escalation study to assess the safety and pharmacodynamics of ISIS 301012 [mipomersen sodium] in hypercholesterolemic subjects on stable statin therapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation

    • Most Recent Events

    • 14 Apr 2010 Results published in the Journal of the American College of Cardiology.
    • 19 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
    • 13 Nov 2007 Results have been reported.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top